Am J Perinatol
DOI: 10.1055/a-2721-5822
Original Article

Impact of Maternal Aspirin Therapy on Neonatal Epigenetic Patterns

Autoren

  • Dante Varotsis

    1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Suhita Gayen nee Betal

    2   Nemours Children's Health, Wilmington, Delaware, United States
  • Sankar Addya

    3   Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Zubair H. Aghai

    2   Nemours Children's Health, Wilmington, Delaware, United States
  • Rupsa C. Boelig

    1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Funding Information This study was funded through NIH grant (P.I.: R.C.B.; U.S. Department of Health and Human Services, National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, grant no.: 3R21HD101127-01S1)

Abstract

Background

Low-dose aspirin (LDA) is an intervention recommended to prevent the development of hypertensive disorders of pregnancy (HDP) in high-risk pregnancies. Maternal conditions such as HDP have been associated with cord blood epigenetic changes including those related to cardiovascular processes; however, it is unclear whether maternal aspirin therapy may impact neonatal epigenetics in otherwise healthy high-risk pregnancy.

Objective

This study aimed to determine if maternal LDA exposure in utero leads to altered DNA methylation in umbilical cord blood cells in term neonates compared with controls not exposed to aspirin, and to identify if these methylation changes alter key pathways in the development of chronic disease.

Methods

Umbilical cord blood was collected from 10 neonates without LDA exposure and 13 neonates with LDA exposure in utero. Patients with hypertensive disorders of pregnancy, COVID-19, and chorioamnionitis were excluded. Genomic DNA was isolated from umbilical cord blood cells and genome-wide DNA methylation was performed using Illumina Methylation EPIC assay.

Results

A total of 155 differentially methylated loci (81 genes were hypermethylated and 74 were hypomethylated) were identified in LDA-exposed neonatal umbilical cord blood compared with the control group. Important canonical pathways identified by Ingenuity Pathway Analysis (IPA) were related to Th1 and Th2 signaling and classical (M1) macrophage activation. The genes affected by LDA exposure were associated with cardiac and renal systems.

Conclusion

LDA exposure led to differential DNA methylation in umbilical cord blood. The differentially methylated genes were related to inflammatory pathways as well as cardiac and renal toxicity pathways. LDA exposure in utero may promote altered health programming in the neonate in areas impacting cardiovascular health.

Key Points

  • Maternal aspirin exposure is associated with differential DNA methylation in cord blood.

  • Cord blood epigenetic changes associated with maternal aspirin relate to anti-inflammatory pathways.

  • Research on potential protective impact of maternal aspirin on neonatal epigenetics is warranted.

Note

This data were presented in part as a poster at the Society for Maternal Fetal Medicine Annual Meeting on February 10, 2023 in San Francisco, CA (Abstract no.: 977).


Ethical Approval

This study was approved by the Thomas Jefferson University Institutional Review Board. Study was based on an IRB for delivery biorepository (August 8, 2019: 19D.587) and secondary analysis of samples collected for this study (March 11 2021: 21F.218), P.I.: R.C.B.




Publikationsverlauf

Eingereicht: 24. Juli 2025

Angenommen: 12. Oktober 2025

Artikel online veröffentlicht:
30. Oktober 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA